Alfredo Addeo

Alfredo Addeo: A True Game Changer in Targeted Therapy for Lung Cancer - OncoDaily Alfredo Addeo: A True Game Changer in Targeted Therapy for Lung Cancer / Alfredo Addeo, CA: A Cancer Journal for Clinicians, cancer, Claudio De Vito, Giuseppe

A True Game Changer in Targeted Therapy for Lung Cancer - Alfredo Addeo
@alfdoc2.bsky.social
@jillfeldman4.bsky.social

oncodaily.com/science/targ...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #TargetedTherapy #LungCancer #TKIs

Two studies investigating efficacy of bispecific T-cell engager tarlatamab and lurbinectedin–atezolizumab combination met their primary endpoints of survival.

Read the opinion by @alfdoc2.bsky.social‬ in the #ESMODailyReporter

🔗 buff.ly/3NXrdAg

#SCLC #LungCancer

Great day one at the 4th #ISLC25 in Rome

OOO

LCC in Italian: Virtual Tumor Board – Resectable Stage III NSCLC | IASLC As part of IASLC's ongoing series of podcasts in world languages, Dr. Alfredo Addeo moderates a discussion in Italian with Dr. Cecilia Pompili and Dr. Franceso ...

Don't miss the new #LungCancerConsidered in Italian! @alfdoc2.bsky.social hosts a discussion with Dr. Cecilia Pompili & Dr. Francesco Passiglia to talk about treating resectable Stage III NSCLC & new therapy options.

🎧 Listen now: bit.ly/ItalianVTB

#LungCancer #NSCLC #Oncology #VTB

Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: From Bedside to Bench and Back - BioDrugs Immunotherapy with checkpoint inhibitors has become the cornerstone of systemic treatment for non-oncogene addicted non-small-cell lung cancer. Despite its pivotal role, a significant proportion of pa...

just hot off the press, our review "Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: From Bedside to Bench and Back". Congrats to all the co-authors , DrBorgeaud Dr Mariniello, Dr Kim, Dr Weiner, Dr Frisone. Here the free access link.springer.com/article/10.1...

IASLC #WCLC2025 is upon us! Your co-chairs cannot wait to welcome you #NoemiReguart 🇪🇸 #IsabelleOpitz🇨🇭 #UmbertoMalapelle 🇮🇹 & a familiar face from🇮🇪

Registration & abstract submissions are OPEN!

Join us in Barcelona | Sept 6–9, 2025 @iaslc.bsky.social @oncoalert.bsky.social #LCSM bit.ly/IASLCWCLC

Leaving X

I can’t continue to support X with a clear conscience.

I hope BlueSky replaces it. But I don’t think it will do so quickly unless we drop X, as opposed to us having feet in both camps.

@drsanjaypopat.bsky.social kicks off @btog.bsky.social Essential Update in therapeutic options for stage 4 NSCLC

✅ all topics covered
✅ stellar speaker line up
✅ full house

👊👊👊

Samreen Ahmed on uncommon EGFR mutations.

Referencing the lovely paper & beautiful figure by @alfdoc2.bsky.social

Distills treatment options really well

Pleased to share our brand-new certification for our Lung Cancer Centre—a unique quality label within the Canton of Geneva. This achievement has been made possible thanks to an incredible team effort, unwavering commitment, and strong support.#University Hospital Geneva

The HTIBM: lessons learned. Episode 6 - Me and Cetnar dance again. @onclive.bsky.social and I were still feeling out what How This is Building Me was a little. I had an evolving people centered model but onclive didn’t want to waste an expert opportunity either.

Opinion | Bluesky Is Different From X. For Now. Users are looking for a more curated experience on a platform that is not constantly trying to get them to interact with brands.

Nice article on movement from Ex to 🦋
www.nytimes.com/2024/12/07/o...

Lovely team-building karaoke all together—it was so much fun! Special thanks to my Neapolitan friends for singing along to Napul’è!

Management of severe immune-related adverse events and outcomes in patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors AbstractBackground. Immune checkpoint inhibitors (ICIs) are associated with severe immune-related adverse events (s-irAEs) that result in hospitalization,

Pleased to share our paper on the impact of severe irAEs in adv NSCLC #TheOncologist
- 3211pts, ConcertAI database
- 8.6% s-irAEs: diarrhea 3.5%, pneu 1.4%
- s-irAEs req steroids/immunosuppression=53%⬆️risk death v no irAE

@oncoalert.bsky.social #MedSky #OncSky #LCSM
academic.oup.com/oncolo/advan...

Howdy, folks! I've arrived! #LCSM @n8pennell.bsky.social @antoniopassaro.bsky.social @stephenvliu.bsky.social

First Cycle Toxicity and Survival in Patients with Rare Cancers Treated with Checkpoint Inhibitors AbstractBackground. Associations between immune-related adverse events (irAEs) from checkpoint inhibitor therapy and outcomes have been previously evaluate

Impact of cycle 1 irAEs on ICI outcomes:
- 683pts from SWOG DART trial
- g1-2 irAEs = ⬆️OS HR 0.61 p < 0.001
- g3+ irAEs = ⬇️OS HR  1.41 p= .025
- g1-2 derm irAE = ⬆️OS v other g1-2 irAE HR 0.67 p=0.002

Congrats @eladsharonmd.bsky.social @oncoalert.bsky.social

academic.oup.com/jnci/advance...

Dr Filippi shares his thoughts on PCI and RT role at the conference on #SCLC at University Hospital Geneva

Dr Menis kicks off our conference on #SCLC at University Hospital Geneva pleased to have such a great expert here today with us

I know many other have done these but I’ve collected almost 100 people and my personal list is hard to share.

go.bsky.app/2mRM9TD

a man is talking to a woman and says my little birds are everywhere . ALT: a man is talking to a woman and says my little birds are everywhere .

Why strew'st thou sugar on that bottled spider, Whose deadly web ensnareth thee about?

Richard III 1.3

#ShakespeareSunday #GameofThrones

@alfdoc2.bsky.social @bensolomon1.bsky.social @prunellab.bsky.social added you, welcome!